Next Article in Journal
Lignin-Based Carbon Nanofibers as Electrodes for Vanadium Redox Couple Electrochemistry
Next Article in Special Issue
Intracellular Imaging with Genetically Encoded RNA-Based Molecular Sensors
Previous Article in Journal
Turn-On Fluorescence Aptasensor on Magnetic Nanobeads for Aflatoxin M1 Detection Based on an Exonuclease III-Assisted Signal Amplification Strategy
Previous Article in Special Issue
Fluorogenic RNA Aptamers: A Nano-platform for Fabrication of Simple and Combinatorial Logic Gates
Article Menu
Issue 1 (January) cover image

Export Article

Open AccessReview

Vectors for Glioblastoma Gene Therapy: Viral & Non-Viral Delivery Strategies

1
Drug Design, Development, and Delivery (4D) Laboratory, Clemson University, Clemson, SC 29634, USA
2
Nanobiotechnology Laboratory, Department of Bioengineering, Clemson University, Clemson, SC 29634, USA
*
Author to whom correspondence should be addressed.
Nanomaterials 2019, 9(1), 105; https://doi.org/10.3390/nano9010105
Received: 13 November 2018 / Revised: 21 December 2018 / Accepted: 3 January 2019 / Published: 16 January 2019
  |  
PDF [1381 KB, uploaded 16 January 2019]
  |  

Abstract

Glioblastoma multiforme is the most common and aggressive primary brain tumor. Even with aggressive treatment including surgical resection, radiation, and chemotherapy, patient outcomes remain poor, with five-year survival rates at only 10%. Barriers to treatment include inefficient drug delivery across the blood brain barrier and development of drug resistance. Because gliomas occur due to sequential acquisition of genetic alterations, gene therapy represents a promising alternative to overcome limitations of conventional therapy. Gene or nucleic acid carriers must be used to deliver these therapies successfully into tumor tissue and have been extensively studied. Viral vectors have been evaluated in clinical trials for glioblastoma gene therapy but have not achieved FDA approval due to issues with viral delivery, inefficient tumor penetration, and limited efficacy. Non-viral vectors have been explored for delivery of glioma gene therapy and have shown promise as gene vectors for glioma treatment in preclinical studies and a few non-polymeric vectors have entered clinical trials. In this review, delivery systems including viral, non-polymeric, and polymeric vectors that have been used in glioblastoma multiforme (GBM) gene therapy are discussed. Additionally, advances in glioblastoma gene therapy using viral and non-polymeric vectors in clinical trials and emerging polymeric vectors for glioma gene therapy are discussed. View Full-Text
Keywords: glioblastoma multiforme; gene therapy; viral vector; non-viral vector; gene delivery; siRNA glioblastoma multiforme; gene therapy; viral vector; non-viral vector; gene delivery; siRNA
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Caffery, B.; Lee, J.S.; Alexander-Bryant, A.A. Vectors for Glioblastoma Gene Therapy: Viral & Non-Viral Delivery Strategies. Nanomaterials 2019, 9, 105.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Nanomaterials EISSN 2079-4991 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top